Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus study

Neurology: Clinical Practice

Volumn 2, Issue 1, 2012, Pages 48-57

  Tornatore, Carlo ^a   Theodore Phillips, J ^b   Khan, Omar ^c   Miller, Aaron E ^d   Barnes, Christopher J ^e  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Infusion Communications Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; FINGOLIMOD; NATALIZUMAB;

ADULT; ARTICLE; BRAIN REGION; CASE REPORT; CLINICAL PRACTICE; DEMYELINATING DISEASE; DISEASE COURSE; FEMALE; HUMAN; MALE; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NEUROLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; RADIOLOGICALLY ISOLATED SYNDROME; UNITED STATES;

EID: 84875823480     PISSN: 21630402     EISSN: 21630933     Source Type: Journal    
DOI: 10.1212/CPJ.0b013e31824cb09b     Document Type: Article

References (20)

1. Smith B, Carson S, Fu R, et al. Drug class review: disease-modifying drugs for multiple sclerosis: final update 1 report [Internet]. In: Drug Class Reviews. Portland, OR: Oregon Health & Science University; 2010.
2. Clegg A, Bryant J. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. Expert Opin Pharmacother 2001;2:623-639.
3. Aktas O, Küry P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 2010;6:373-382.
4. TYSABRI (natalizumab) prescribing information (2012). http://www.tysabri.com/en-US/tysb/site/pdfs/TYSABRI-pi.pdf. Accessed February 4, 2011.
5. Gold R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs 2011;25:37-52.
6. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
7. Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 2011;76(suppl 1):S14-S25.
8. Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007;6:677-686.
9. Montalban X, Tintoré M, Swanton J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010;74:427-434.
10. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
11. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-1174.
12. Tumani H, Deisenhammer F, Giovannoni G, et al. Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol 2011;70:520.
13. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005;62:865-870.
14. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsingremitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011;10:520-529.
15. Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009;72:800-805.
16. Okuda DT, Mowry EM, Cree BA, et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 2011;76:686-692.
17. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-2069.
18. Barkhof F, Simon JH, Fazekas F, et al. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol 2011;8:13-21.
19. Filippi M, Rocca MA. The role of magnetic resonance imaging in the study of multiple sclerosis: diagnosis, prognosis and understanding disease pathophysiology. Acta Neurol Belg 2011;111:89-98.
20. Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis. Clin Neurol Neurosurg 2001;103:1-11.